aristolochic acid i has been researched along with Chronic Kidney Diseases in 20 studies
aristolochic acid I: phospholipase A inhibitor
aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Described in the 1950s, Balkan Endemic Nephropathy (BEN) has been recognized as a chronic kidney disease (CKD) with clinical peculiarities and multiple etiological factors." | 6.82 | Aristolochic acid I as an emerging biogenic contaminant involved in chronic kidney diseases: A comprehensive review on exposure pathways, environmental health issues and future challenges. ( Drăghia, LP; Lukinich-Gruia, AT; Milovanović, D; Nortier, J; Păunescu, V; Pavlović, NM; Popović, M; Tatu, CA, 2022) |
| "Generally, renal aging is accompanied by renal fibrosis, which is the final common pathway of chronic kidney diseases." | 5.62 | Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice. ( Abe, E; Atobe, Y; Azushima, K; Funakoshi, K; Kanaoka, T; Kinguchi, S; Suzuki, T; Taguchi, S; Tamura, K; Tanaka, S; Tsukamoto, S; Uneda, K; Urate, S; Wakui, H; Yamaji, T; Yamashita, A, 2021) |
| "Described in the 1950s, Balkan Endemic Nephropathy (BEN) has been recognized as a chronic kidney disease (CKD) with clinical peculiarities and multiple etiological factors." | 2.82 | Aristolochic acid I as an emerging biogenic contaminant involved in chronic kidney diseases: A comprehensive review on exposure pathways, environmental health issues and future challenges. ( Drăghia, LP; Lukinich-Gruia, AT; Milovanović, D; Nortier, J; Păunescu, V; Pavlović, NM; Popović, M; Tatu, CA, 2022) |
| " Two major genetic factors that are discussed include genetic polymorphisms in plasma membrane transporters that catalyze uptake and accumulation or efflux and elimination of environmental chemicals, and genetic polymorphisms in bioactivation enzymes that generate toxic and reactive metabolites." | 2.61 | Environmental and Genetic Factors Influencing Kidney Toxicity. ( Lash, LH, 2019) |
| "Notably, ESRD-associated HAS had a significantly higher TMB (17." | 1.91 | Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. ( Chang, CJ; Chang, IY; Chen, CC; Chen, KH; Chen, TC; Chuang, HC; Hsieh, TY; Huang, HY; Huang, SC; Lin, IC; Liu, H; Liu, TT; Ng, KF, 2023) |
| "Generally, renal aging is accompanied by renal fibrosis, which is the final common pathway of chronic kidney diseases." | 1.62 | Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice. ( Abe, E; Atobe, Y; Azushima, K; Funakoshi, K; Kanaoka, T; Kinguchi, S; Suzuki, T; Taguchi, S; Tamura, K; Tanaka, S; Tsukamoto, S; Uneda, K; Urate, S; Wakui, H; Yamaji, T; Yamashita, A, 2021) |
| " This integrated microphysiological system provides an ex vivo approach for investigating organ-organ interactions, whereby the metabolism of a drug or other xenobiotic by one tissue may influence its toxicity toward another, and represents an experimental approach for studying chemical toxicity related to environmental and other toxic exposures." | 1.46 | Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. ( Chang, SY; Chapron, A; Dickman, KG; Eaton, DL; Gao, C; Grollman, AP; Himmelfarb, J; Kelly, EJ; Mao, Q; Neumann, T; Rosenquist, TA; Shen, D; Sidorenko, VS; Wang, J; Weber, EJ; Yeung, CK, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 9 (45.00) | 2.80 |
| Authors | Studies |
|---|---|
| Urate, S | 3 |
| Wakui, H | 3 |
| Azushima, K | 2 |
| Yamaji, T | 3 |
| Suzuki, T | 3 |
| Abe, E | 3 |
| Tanaka, S | 3 |
| Taguchi, S | 2 |
| Tsukamoto, S | 2 |
| Kinguchi, S | 3 |
| Uneda, K | 1 |
| Kanaoka, T | 1 |
| Atobe, Y | 1 |
| Funakoshi, K | 1 |
| Yamashita, A | 2 |
| Tamura, K | 3 |
| Kamimura, D | 1 |
| Sasaki, K | 1 |
| Terker, AS | 1 |
| Tang, J | 1 |
| Cao, S | 1 |
| Arroyo, JP | 1 |
| Niu, A | 1 |
| Wang, S | 1 |
| Fan, X | 1 |
| Zhang, Y | 1 |
| Bennett, SR | 1 |
| Zhang, MZ | 1 |
| Harris, RC | 1 |
| Lukinich-Gruia, AT | 1 |
| Nortier, J | 1 |
| Pavlović, NM | 1 |
| Milovanović, D | 1 |
| Popović, M | 1 |
| Drăghia, LP | 1 |
| Păunescu, V | 1 |
| Tatu, CA | 1 |
| Huang, SC | 1 |
| Chang, IY | 1 |
| Chang, CJ | 1 |
| Liu, H | 1 |
| Chen, KH | 1 |
| Liu, TT | 1 |
| Hsieh, TY | 1 |
| Chuang, HC | 1 |
| Chen, CC | 1 |
| Lin, IC | 1 |
| Ng, KF | 1 |
| Huang, HY | 1 |
| Chen, TC | 1 |
| Ren, J | 1 |
| Rudemiller, NP | 1 |
| Wen, Y | 1 |
| Lu, X | 1 |
| Privratsky, JR | 1 |
| Crowley, SD | 1 |
| Chang, JF | 1 |
| Hsieh, CY | 1 |
| Lu, KC | 1 |
| Chen, YW | 1 |
| Liang, SS | 1 |
| Lin, CC | 1 |
| Hung, CF | 1 |
| Liou, JC | 1 |
| Wu, MS | 1 |
| Wang, X | 1 |
| Xue, N | 1 |
| Zhao, S | 1 |
| Shi, Y | 1 |
| Ding, X | 1 |
| Fang, Y | 1 |
| Ishii, T | 1 |
| Kumagae, T | 1 |
| Kobayashi, R | 1 |
| Haruhara, K | 1 |
| Nakamura, T | 1 |
| Kobayashi, S | 1 |
| Succar, L | 1 |
| Pianta, TJ | 1 |
| Davidson, T | 1 |
| Pickering, JW | 1 |
| Endre, ZH | 1 |
| Chang, SY | 1 |
| Weber, EJ | 1 |
| Sidorenko, VS | 1 |
| Chapron, A | 1 |
| Yeung, CK | 1 |
| Gao, C | 1 |
| Mao, Q | 1 |
| Shen, D | 1 |
| Wang, J | 1 |
| Rosenquist, TA | 1 |
| Dickman, KG | 1 |
| Neumann, T | 1 |
| Grollman, AP | 2 |
| Kelly, EJ | 1 |
| Himmelfarb, J | 1 |
| Eaton, DL | 1 |
| Honarpisheh, M | 1 |
| Foresto-Neto, O | 1 |
| Steiger, S | 1 |
| Kraft, F | 1 |
| Koehler, P | 1 |
| von Rauchhaupt, E | 1 |
| Potempa, J | 1 |
| Adamowicz, K | 1 |
| Koziel, J | 1 |
| Lech, M | 1 |
| Lash, LH | 1 |
| Scarpellini, A | 1 |
| Huang, L | 1 |
| Burhan, I | 1 |
| Schroeder, N | 1 |
| Funck, M | 1 |
| Johnson, TS | 1 |
| Verderio, EA | 1 |
| Hsieh, CF | 1 |
| Huang, SL | 1 |
| Chen, CL | 1 |
| Chen, WT | 1 |
| Chang, HC | 1 |
| Yang, CC | 1 |
| Antoine, MH | 1 |
| Debelle, F | 1 |
| Piccirilli, J | 1 |
| El Kaddouri, F | 1 |
| Declèves, AE | 1 |
| De Prez, E | 1 |
| Husson, C | 1 |
| Mies, F | 1 |
| Bourgeade, MF | 1 |
| Nortier, JL | 1 |
| Weaver, VM | 2 |
| Fadrowski, JJ | 2 |
| Jaar, BG | 1 |
| Weidemann, DK | 1 |
| Chen, H | 1 |
| Cao, G | 1 |
| Chen, DQ | 1 |
| Wang, M | 1 |
| Vaziri, ND | 1 |
| Zhang, ZH | 1 |
| Mao, JR | 1 |
| Bai, X | 1 |
| Zhao, YY | 1 |
| Marcus, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Development of a Diagnostic Kit for Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis[NCT03487861] | 1,000 participants (Anticipated) | Observational | 2017-08-29 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for aristolochic acid i and Chronic Kidney Diseases
| Article | Year |
|---|---|
Aristolochic acid I as an emerging biogenic contaminant involved in chronic kidney diseases: A comprehensive review on exposure pathways, environmental health issues and future challenges.
Topics: Aristolochic Acids; Balkan Nephropathy; Environmental Health; Female; Humans; Male; Renal Insufficie | 2022 |
Environmental and Genetic Factors Influencing Kidney Toxicity.
Topics: Activation, Metabolic; Acute Kidney Injury; Aristolochic Acids; Arsenic; Cadmium; Drug Contamination | 2019 |
Toxic environmental exposures and kidney health in children.
Topics: Adolescent; Aristolochic Acids; Child; Disease Progression; Dysuria; Environmental Exposure; Humans; | 2016 |
17 other studies available for aristolochic acid i and Chronic Kidney Diseases
| Article | Year |
|---|---|
Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice.
Topics: Aging; Animals; Aristolochic Acids; beta-Galactosidase; Collagen; Cyclin-Dependent Kinase Inhibitor | 2021 |
Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy.
Topics: Albuminuria; Animals; Aristolochic Acids; Collagen; Disease Models, Animal; Etanercept; Fibrosis; In | 2021 |
Macrophage interferon regulatory factor 4 deletion ameliorates aristolochic acid nephropathy via reduced migration and increased apoptosis.
Topics: Animals; Apoptosis; Aristolochic Acids; Cells, Cultured; Disease Models, Animal; DNA; DNA Mutational | 2022 |
Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure.
Topics: Hemangiosarcoma; Humans; Incidence; Kidney Failure, Chronic; Liver Neoplasms; Mutation; Renal Insuff | 2023 |
The transcription factor Twist1 in the distal nephron but not in macrophages propagates aristolochic acid nephropathy.
Topics: Animals; Apoptosis; Aristolochic Acids; Coculture Techniques; Disease Models, Animal; Epithelial Cel | 2020 |
Therapeutic Targeting of Aristolochic Acid Induced Uremic Toxin Retention, SMAD 2/3 and JNK/ERK Pathways in Tubulointerstitial Fibrosis: Nephroprotective Role of Propolis in Chronic Kidney Disease.
Topics: Animals; Aristolochic Acids; Cresols; Disease Models, Animal; Epithelial-Mesenchymal Transition; Ext | 2020 |
Upregulation of miR-382 contributes to renal fibrosis secondary to aristolochic acid-induced kidney injury via PTEN signaling pathway.
Topics: Animals; Aristolochic Acids; Base Sequence; Cells, Cultured; Epithelial Cells; Epithelial-Mesenchyma | 2020 |
Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Fibrosis; Humans; Kidney Tubules; Male; Mice; R | 2021 |
Subclinical chronic kidney disease modifies the diagnosis of experimental acute kidney injury.
Topics: Acute Kidney Injury; Adenine; Animals; Aristolochic Acids; Biomarkers; Cell Adhesion Molecules; Chem | 2017 |
Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity.
Topics: Animals; Aristolochic Acids; Biomarkers; Biotransformation; Carcinogens; Dicumarol; Epithelial Cells | 2017 |
Aristolochic acid I determine the phenotype and activation of macrophages in acute and chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Cisplatin; Disease Models, Animal; Female; Fibrosi | 2018 |
Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis.
Topics: Animals; Aristolochic Acids; Fibrosis; GTP-Binding Proteins; Male; Mice; Mice, Inbred C57BL; Mice, K | 2014 |
Non-aristolochic acid prescribed Chinese herbal medicines and the risk of mortality in patients with chronic kidney disease: results from a population-based follow-up study.
Topics: Aristolochic Acids; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Longitudinal Studies; | 2014 |
Human bone morphogenetic protein-7 does not counteract aristolochic acid-induced renal toxicity.
Topics: Animals; Aristolochic Acids; beta Catenin; Bone Morphogenetic Protein 7; Cell Line; Fibronectins; Fi | 2015 |
Global dimensions of chronic kidney disease of unknown etiology (CKDu): a modern era environmental and/or occupational nephropathy?
Topics: Aristolochic Acids; Arsenic; Cadmium; Central America; Egypt; Humans; India; Lead; Occupational Expo | 2015 |
Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression.
Topics: Adenine; Animals; Aristolochic Acids; Biomarkers; Disease Models, Animal; Disease Progression; Early | 2016 |
Global hazards of herbal remedies: lessons from Aristolochia: The lesson from the health hazards of Aristolochia should lead to more research into the safety and efficacy of medicinal plants.
Topics: Animals; Aristolochia; Biomedical Research; Carcinogens; Dietary Supplements; Epidemiologic Studies; | 2016 |